Full Press Release Details
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences:
H.C. Wainwright 4thAnnual Nasdaq BioConnect Conference
Format: Fireside chat and investor meetingsDate: Tuesday, May 19th, 2026Time: 2:30 p.m. ET
Jefferies Global Healthcare Conference
Format: Corporate presentation and investor meetingsDate: Wednesday, June 3rd, 2026Time: 3:10 p.m. ET
Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website atir.kyvernatx.com. Replays of the webcasts will be available on the website for 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience. For more information, please visithttps://kyvernatx.com.